Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
-
Data Presented at the 2023 Military Health System Research Symposium show activity in animal model of acute spinal cord injury-induced immobilization BELTSVILLE, Md., Sept. 05, 2023 (GLOBE...
-
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
-
Phase 1b data for NC410 and further updates on other clinical programs expected in the fourth quarter of 2023Cash of approximately $131 million expected to fund operations into mid-2025 BELTSVILLE,...
-
BELTSVILLE, Md., June 21, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
-
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
-
Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs First patient dosed with NC525 (LAIR-1 mAb) in a Phase 1 trial in acute myeloid leukemia (AML) Cash of approximately $145...
-
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
-
Clinical data updates expected in 2023 for all three programsNC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML)Ended 2022 with approximately $160 million in cash...
-
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...